{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:55:20Z","timestamp":1780109720019,"version":"3.54.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"},{"name":"Competence Network IBD"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The prospective RUN-CD registry investigates the effectiveness of ustekinumab (UST) and other biologics in Crohn\u2019s disease (CD) across Germany. Based on data from the registry, this study presents the maintenance phase results of a 12-month real-world-evidence (RWE) comparison of CD patients initiating new biologic therapies with UST or anti-TNF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>After excluding patients using biologics other than UST and anti-TNF and those with missing outcomes, the final sample consisted of 618 CD patients. Clinical remission (CR), defined as a Harvey-Bradshaw Index (HBI)\u2005\u22644, was the prespecified endpoint at 12 months. Switching to another biologic therapy was considered an outcome failure. Propensity score adjustment was used to reduce the effect of confounders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 343 CD patients treated with UST and 264 treated with anti-TNF. Over 12 months, the frequency of therapy switches was significantly higher for infliximab (28%) compared with UST (17%) and adalimumab (17%) (P\u2005=.045). There was no significant difference in CR rates at 12 months between the UST and anti-TNF groups (65.8% vs 60.0%, P\u2005=.262). However, in week-16 responders, CR rates at 12 months were significantly higher with UST (77.6%) versus anti-TNF (65.4%) (P\u2005=.041). The change in EQ-VAS (QoL) scores between UST and anti-TNF showed a 5.1-point difference favoring UST (P\u2005=.002).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this 12-month RWE comparison, overall CR rates were similar between UST and anti-TNF. However, among week-16 responders, CR rates were significantly higher with UST. Additionally, UST was associated with a significantly greater improvement in QoL compared with anti-TNF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf051","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T08:36:57Z","timestamp":1743237417000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn\u2019s disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2016-6991","authenticated-orcid":false,"given":"Bernd","family":"Bokemeyer","sequence":"first","affiliation":[{"name":"Interdisciplinary Crohn Colitis Centre Minden ,","place":["Germany"]},{"name":"Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein , Campus Kiel ,","place":["Germany"]},{"name":"Competence Network IBD , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Plachta-Danielzik","sequence":"additional","affiliation":[{"name":"Competence Network IBD , Kiel ,","place":["Germany"]},{"name":"Institute of Human Nutrition and Food Science, Christian-Albrechts University , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Gilman","sequence":"additional","affiliation":[{"name":"Competence Network IBD , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"di Giuseppe","sequence":"additional","affiliation":[{"name":"Competence Network IBD , Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert","family":"Deppe","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Minden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Mohl","sequence":"additional","affiliation":[{"name":"Centre for Gastroenterology Saar , Saarbr\u00fccken ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8101-4521","authenticated-orcid":false,"given":"Niels","family":"Teich","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Leipzig ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hoffstadt","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Iserlohn ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schweitzer","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , M\u00fcnster ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manfred","family":"von der Ohe","sequence":"additional","affiliation":[{"name":"Gastroenterologische Gemeinschaftspraxis , Herne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Gauss","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Internal Medicine IV, University Clinics of Heidelberg , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-8433","authenticated-orcid":false,"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[{"name":"First Department of Medicine, Erlangen University Hospital, Friedrich-Alexander-University Erlangen-Nuremberg , Erlangen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Krause","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Kassel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Blumenstein","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Clinical Nutrition, Johann Wolfgang Goethe University Clinic , Frankfurt ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Gastroenterology Practice , Minden ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[{"name":"Clinic of General Internal Medicine I, University Hospital Schleswig-Holstein , Campus Kiel ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"2025042106114728700_CIT0001","first-page":"123","article-title":"The diagnosis and treatment of Crohn\u2019s disease and ulcerative colitis","volume":"106","author":"Baumgart","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"2025042106114728700_CIT0002","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","article-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut."},{"key":"2025042106114728700_CIT0003","first-page":"300","article-title":"Measuring disability in IBD: the IBD disability index","volume":"9","author":"Colombel","year":"2013","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"2025042106114728700_CIT0004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000360720","article-title":"IBD therapy: new targets and unmet needs","volume":"79","author":"Colombel","year":"2014","journal-title":"Nestle Nutr Inst Workshop Ser"},{"key":"2025042106114728700_CIT0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.drudis.2015.07.005","article-title":"Addressing unmet needs in inflammatory bowel disease","volume":"20","author":"Bokemeyer","year":"2015","journal-title":"Drug Discov Today."},{"key":"2025042106114728700_CIT0006","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2025042106114728700_CIT0007","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"2025042106114728700_CIT0008","first-page":"139","article-title":"Remicade((R)) (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"key":"2025042106114728700_CIT0009","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut."},{"key":"2025042106114728700_CIT0010","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet."},{"key":"2025042106114728700_CIT0011","doi-asserted-by":"crossref","first-page":"17562848211010668","DOI":"10.1177\/17562848211010668","article-title":"Head-to-head comparison of biological drugs for inflammatory bowel disease: from randomized controlled trials to real-world experience","volume":"14","author":"Macaluso","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"2025042106114728700_CIT0012","doi-asserted-by":"crossref","first-page":"245","DOI":"10.14740\/gr1194","article-title":"Comparative effectiveness of ustekinumab versus adalimumab in induction of clinical response and remission in Crohn\u2019s Disease: experience of a real-world cohort at a tertiary care inflammatory bowel disease referral center","volume":"12","author":"Ahmed","year":"2019","journal-title":"Gastroenterology Res."},{"key":"2025042106114728700_CIT0013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn\u2019s disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025042106114728700_CIT0014","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1080\/00365521.2017.1373847","article-title":"Ustekinumab use in Crohn\u2019s disease: a Canadian tertiary care centre experience","volume":"52","author":"Greenup","year":"2017","journal-title":"Scand J Gastroenterol."},{"key":"2025042106114728700_CIT0015","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn\u2019s disease: real-world experience from a multicenter cohort study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2025042106114728700_CIT0016","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/apt.14016","article-title":"Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort","volume":"45","author":"Ma","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"2025042106114728700_CIT0017","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn\u2019s disease patients: a multicentre experience","volume":"47","author":"Wils","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2025042106114728700_CIT0018","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/ecco-jcc\/jjy222.442","article-title":"P318 Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort","volume":"13","author":"Gadhok","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2025042106114728700_CIT0019","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.dld.2019.05.002","article-title":"Effectiveness and safety of Ustekinumab for Crohn\u2019s disease; systematic review and pooled analysis of real-world evidence","volume":"51","author":"Engel","year":"2019","journal-title":"Dig Liver Dis."},{"key":"2025042106114728700_CIT0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s disease results of the ICC registry, a nationwide prospective observational cohort study","volume":"14","author":"Biemans","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2025042106114728700_CIT0021","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/apt.15371","article-title":"Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn\u2019s disease: results from the ENEIDA registry","volume":"50","author":"Iborra","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2025042106114728700_CIT0022","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/ecco-jcc\/jjz080","article-title":"Long-term clinical effectiveness of ustekinumab in patients with Crohn\u2019s disease who failed biologic therapies: a National Cohort Study","volume":"13","author":"Liefferinckx","year":"2019","journal-title":"J Crohns Colitis."},{"key":"2025042106114728700_CIT0023","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/apt.15958","article-title":"Real-world long-term effectiveness of ustekinumab in Crohn\u2019s disease: results from the ENEIDA registry","volume":"52","author":"Iborra","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2025042106114728700_CIT0024","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1093\/ibd\/izac271","article-title":"Real-world comparative effectiveness of ustekinumab vs anti-TNF in Crohn\u2019s disease with propensity score adjustment: induction phase results from the prospective, observational RUN-CD Study","volume":"29","author":"Bokemeyer","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025042106114728700_CIT0025","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1055\/s-0034-1385199","article-title":"Aktualisierte S3-leitlinie \u2013 \u201ediagnostik und therapie des morbus crohn\u201c2014","volume":"52","author":"Preiss","year":"2014","journal-title":"Z Gastroenterol."},{"key":"2025042106114728700_CIT0026","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2025042106114728700_CIT0027","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1093\/ibd\/izab357","article-title":"Long-term real-world effectiveness and safety of ustekinumab in Crohn\u2019s disease patients: The SUSTAIN Study","volume":"28","author":"Chaparro","year":"2022","journal-title":"Inflamm Bowel Dis."},{"key":"2025042106114728700_CIT0028","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Ser B Method."},{"key":"2025042106114728700_CIT0029","first-page":"Paper 312","article-title":"Handling missing data by maximum likelihood","volume":"2012","author":"Allison","year":"2012","journal-title":"SAS Global Forum."},{"key":"2025042106114728700_CIT0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2025042106114728700_CIT0031","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med."},{"key":"2025042106114728700_CIT0032","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10464-013-9604-4","article-title":"Drawing causal inferences using propensity scores: a practical guide for community psychologists","volume":"52","author":"Lanza","year":"2013","journal-title":"Am J Community Psychol."},{"key":"2025042106114728700_CIT0033","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/ibd\/izad1138","article-title":"Real-world effectiveness of vedolizumab vs anti-TNF in biologic-naive crohn\u2019s disease patients: a 2-year propensity-score-adjusted analysis from the VEDOIBD-Study","volume":"30","author":"Bokemeyer","year":"2023","journal-title":"Inflamm Bowel Dis."},{"key":"2025042106114728700_CIT0034","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00384-020-03588-w","article-title":"Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting","volume":"35","author":"Bokemeyer","year":"2020","journal-title":"Int J Colorectal Dis."},{"key":"2025042106114728700_CIT0035","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2468-1253(21)00474-X","article-title":"Treat to target versus standard of care for patients with Crohn\u2019s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial","volume":"7","author":"Danese","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf051\/62705486\/jjaf051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjaf051\/62705486\/jjaf051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/4\/jjaf051\/62705486\/jjaf051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:12:08Z","timestamp":1745230328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf051\/8093421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf051","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,25]]},"article-number":"jjaf051"}}